We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Esomeprazole: In Gastroesophageal Reflux Disease in Children and Adolescents.
- Authors
Croxtall, Jamie D.; Perry, Caroline M.; Keating, Gillian M.
- Abstract
▴ Esomeprazole is the S-isomer of the proton pump inhibitor omeprazole and, administered orally, has been evaluated in the management of gastroesophageal reflux disease (GERD) in children aged 111 years and adolescents aged 1217 years. Further studies in children are ongoing.▴ In an 8-week, randomized, double-blind, multicenter trial, a significant improvement from baseline in parent-rated GERD symptom scores was seen in children with endoscopically proven GERD aged 111 years stratified to receive oral esomeprazole 5 or 10 mg (in those weighing <20 kg) or 10 or 20 mg (in those weighing ≥20 kg) once daily. A substudy demonstrated improved or healed erosive esophagitis in the majority of children following esomeprazole therapy.▴ A significant improvement from baseline in parent- or patient-rated GERD-related symptom scores was observed in adolescents aged 1217 years with clinically diagnosed GERD who received oral esomeprazole 20 or 40 mg once daily for 8 weeks in a randomized, double-blind, multicenter trial.▴ Esomeprazole was generally well tolerated in children aged 111 years and adolescents aged 1217 years with GERD, according to the results of well designed, short-term trials.(Table is included in full-text article.)
- Subjects
ESOMEPRAZOLE; PROTON pump inhibitors; PEDIATRIC pharmacology; PHARMACOKINETICS; GASTROESOPHAGEAL reflux in children; MEDICAL research; THERAPEUTICS
- Publication
Pediatric Drugs, 2008, Vol 10, Issue 3, p199
- ISSN
1174-5878
- Publication type
Article
- DOI
10.2165/00148581-200810030-00008